Pfizer’s Strategic Deal with the Trump Administration: A Masterstroke in Corporate Diplomacy In a move that has sent ripples through the pharmaceutical and political landscapes, Pfizer has announced a landmark agreement with the Trump administration to lower drug prices and invest heavily in domestic manufacturing. This three-year agreement, which runs through the end of the current administration’s term, is viewed …
Read More »
Introduction: Shifting the Paradigm in Alzheimer’s Research The landscape of Alzheimer’s disease (AD) research is undergoing a significant transformation. For decades, the focus has been on the amyloid hypothesis, with a multitude of clinical trials targeting amyloid-beta plaques, often with disappointing results. However, recent developments, including the NIA’s strategic funding of novel approaches, signal a new era. The award of …
Read More »Executive Summary Gait variability—particularly stride-time variability (STV) and stride-length variability—has emerged as a promising but context-dependent digital signal for Parkinson’s disease (PD). Across recent studies, STV is repeatedly sensitive to disease state and intervention effects, yet its interpretability hinges on speed control, environment (overground vs treadmill), fatigue, footwear, and surface. Real-world, continuous measurement via wearables is accelerating, and combining gait …
Read More »
promptsyndicate.ai GenAI-powered platform built for a 2030 world — where smartphones are the new printing press